We’re the leading resource for those affected by bleeding disorders. You can count on our organization to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.

News & Events

The goal of this effort is to create and maintain state-of-the-art guidelines on the diagnosis and management of VWD.

Catalyst Biosciences, Inc. recently released an update relevant to an ongoing Phase 1/2 clinical trial for CB 2679d/ISU304, the company’s investigational therapy for the treatment of patients with severe hemophilia B/factor IX (FIX) deficiency. Catalyst develops its therapies using engineered proteases, enzymes that increase the rate of chemical reactions within cells. These proteases can target the proteins associated with certain underlying diseases and conditions, such as FIX.

Because of their lower factor levels, hemophilia patients are generally thought to be better protected from cardiovascular disease (CVD). To determine whether data would support this long-held assumption, a team of investigators enrolled patients from 19 U.S. hemophilia treatment center (HTCs) in the “CVD in Hemophilia” study. The lead author of the study was Barbara Konkle, MD, Professor of Medicine in the Division of Hematology at the University of Washington School of Medicine in Seattle, WA.

HTC Studies Cardiovascular Disease in Hemophilia Patients

Investigators looked into whether having hemophilia protected patients against cardiovascular disease.

Update on Latest ACA Lawsuit

More information on how the current ACA lawsuit could affect the bleeding disorders community.

View Archives

SUBSCRIBE TO OUR NEWSLETTER

Fill in the fields below to receive our email newsletter.